Clinical evidence shows that AposHealth (an FDA-cleared medical device) improves pain, stiffness, and function in people with knee osteoarthritis.
However, it’s uncertain if these improvements are clinically meaningful. The analyses suggest that AposHealth is cost saving by £1,958 per person when compared with standard care if knee surgery is delayed for 5 years. Because the evidence for the potential cost savings is limited, further data collection is recommended to understand if cost savings are made once AposHealth is used in the NHS.
Recent Posts
Childhood Immunization Reforms: Aligning U.S. Schedules with Global Standards
Aligning U.S. Childhood Immunization Schedules with International Benchmarks
Recent childhood immunization reforms by the U.S. Centers for Disease Control and Prevention (CDC) follow a presidential directive...
mRNA Vaccine Advancements: Transforming Infectious Disease Prevention and Equity
Recent mRNA vaccine advancements are poised to transform global health by expanding beyond COVID-19 to tackle neglected infectious diseases and even therapeutic uses. Experts forecasting breakthroughs for 2026 highlight how these innovations use lipid nanoparticles to deliver RNA sequences encodi...
INFARMED Leadership Appointments: A New Era in Health Regulation and Expertise
INFARMED Leadership Appointments: Renewed Expertise for Medicines Oversight
The Portuguese Council of Ministers has issued